Lowest Price Guaranteed
Pages
266
Last Updated
April 2026
View Count
17877
Chapter 2 is an executive summary of the insights captured during our research. The chapter offers a high-level view on the likely evolution of the metabolomics services market in the short to mid-term and long term.
Chapter 3 provides a general introduction to metabolomics, featuring information on various steps involved in the overall process. Further, it provides a detailed discussion on different approaches for metabolomics. In addition, the chapter includes details related to various applications and challenges associated with metabolomic studies. The chapter concludes with a discussion on key growth drivers, as well as upcoming trends in this field.
Chapter 4 includes detailed assessment of the overall landscape of the players offering metabolomics services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters (North America, Europe, Asia, Middle East and North Africa and Rest of The World). The chapter also provides details related to pre-profiling service(s) offered (experiment design and sample preparation), metabolomics service(s) offered (targeted metabolomics, untargeted metabolomics and unknown metabolite identification), additional services offered (lipidomics, metabolic flux analysis, proteomics, and xenobiotic metabolites analysis), type of metabolome profiling technique used (mass spectrometry, nuclear magnetic resonance, liquid chromatography, gas chromatography, inductively coupled plasma spectroscopy, capillary electrophoresis), type of approach used for data analysis (multivariate analysis, univariate analysis, preprocess and normalization, clustering analysis, enrichment analysis and classification and feature selection), type of biological sample analyzed (biological fluids, tissues, cells and stool), source of biological sample (animal, microbe, human and plant), and area of application (biomarker discovery, disease diagnostics, drug discovery, toxicological testing and personalized medicine).
Chapter 5 features an analysis, highlighting the contemporary market trends through eight schematic representations, including waffle chart representations based on regional distribution of various industry and non-industry players, world map representations based on the country-wise distribution of various industry and non-industry players, a horizontally stacked bar chart representation based on company / organization size and type of service provider, a mekko chart representation based on area of application and company / organization size, a vertically stacked bar chart representation based on type of metabolome profiling technique used and type of biological sample analyzed, a tree map representation based on type of metabolome profiling technique and area of application, a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, number of metabolomics services offered, company / organization size and region), and a grid representation based on company / organization size, region, type of metabolomics services offered, type of metabolome profiling technique used and area of application.
Chapter 6 provides an in-depth competitiveness analysis of metabolomics service providers, segmented into four categories, namely large and very large (>500 employees), mid-sized (51-500 employees), small (11-50 employees) and very small companies (<10 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience), their respective capabilities (number of pre-profiling profiling services offered, number of additional services offered, type of metabolome profiling technique used, type of approach used for data analysis, type of biological sample analysed, source of biological sample analysed and area of application) and partnership activity (in terms of number of partnerships and type of agreement).
Chapter 7 includes detailed profiles of prominent players (shortlisted based on company competitiveness analysis) engaged in providing metabolomics services. Each profile features a brief overview of the company including information on several relevant parameters such as (year of establishment, number of employees, location of headquarters and key executives). Further, the chapter also features details on recent developments and an informed future outlook.
Chapter 8 features an insightful analysis of the various partnerships and collaborations that have been inked amongst players in this market, since 2014. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (research agreements, R&D agreements, commercialization agreements, metabolomics data sharing agreements, acquisitions, service alliances, product development agreements, and other related agreements), type of partner (academic / research institutes, pharma / biotech firms, contract research organizations), type of metabolomics service(s) offered (targeted metabolomics and untargeted metabolomics), type of metabolome profiling technique used (LC-MS, GC-MS, NMR), area of application (biomarker discovery, disease diagnostics, drug discovery) and regional distribution of the collaborations.
Chapter 9 features an insightful framework depicting the implementation of several advanced tools and technologies, such as artificial intelligence, big data analytics, block chain, cloud computing, deep learning, machine learning, and quantum computing, at different stages of a metabolomics study, which can assist service providers to address unmet needs associated with such services. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.
Chapter 10 presents an insightful market forecast analysis, highlighting the future potential of metabolomics services market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] area of application (biomarker discovery, personalized medicine, disease diagnostics, drug discovery and toxicological testing), [B] type of metabolomics services (targeted metabolomics and untargeted metabolomics), [C] type metabolome profiling techniques (LC-MS, GC-MS and NMR), [D] type of end user (academic / research institutes, pharma / biotech firms, and CROs) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world).
Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 12 provides the transcripts of interviews conducted with several key stakeholders of this market. In this chapter, we have presented the details of our conversation with Olivier Schmitz (Head of Metabolome Data Science, BASF Metabolome Solutions), Manoj Kumar (Indian Partner - Eroth Technologies, biocrates life sciences), Bernhard Drotleff (Scientific Officer, European Molecular Biology Laboratory), Morten Danielsen (Chief Executive Officer, MS-Omics) and Gilbert Skorski (Chairman and Chief Executive Officer, Phylogene).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Metabolomics
3.3. Steps Involved in a Metabolomics Study
3.3.1. Experimental Design
3.3.2. Sample Preparation
3.3.3. Data Acquisition
3.3.4. Data Processing
3.3.5. Statistical Analysis
3.4. Approaches Used for Metabolomics Analysis
3.4.1. Targeted Metabolomics
3.4.2. Untargeted Metabolomics
3.4.3. Unknown Metabolite Identification
3.5. Applications of Metabolomics
3.6. Challenges Related to Metabolomics
3.7. Need for Outsourcing Metabolomics Operations
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Metabolomics Service Providers: Overall Market Landscape
4.3. Metabolomics Service Providers: Industry Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.3.5. Analysis by Type of Metabolomic Service(s) Offered
4.3.6. Analysis by Type of Additional Service(s) Offered
4.3.7. Analysis by Type of Metabolome Profiling Technique Used
4.3.8. Analysis by Type of Approach Used for Data Analysis
4.3.9. Analysis by Type of Biological Sample Analyzed
4.3.10. Analysis by Source of Biological Sample
4.3.11. Analysis by Area of Application
4.4. Metabolomics Service Providers: Non-Industry Players
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Organization Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.4.5. Analysis by Type of Metabolomic Service(s) Offered
4.4.6. Analysis by Type of Additional Service(s) Offered
4.4.7. Analysis by Type of Metabolome Profiling Technique Used
4.4.8. Analysis by Type of Approach Used for Data Analysis
4.4.9. Analysis by Type of Biological Sample Analyzed
4.4.10. Analysis by Source of Biological Sample
4.4.11. Analysis by Area of Application
5. KEY INSIGHTS
5.1. Chapter Overview
5.1.1. Analysis by Location of Headquarters and Type of Service Provider (Waffle Chart and World Map Representation)
5.1.2. Analysis by Company / Organization Size and Type of Service Provider (Horizontally Stacked Bar Chart)
5.1.3. Analysis by Area of Application and Company / Organization Size (Mekko Chart)
5.1.4. Analysis by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed (Vertically Stacked Bar Chart)
5.1.5. Analysis by Type of Metabolome Profiling Technique Used and Area of Application (Treemap Representation)
5.1.6. Analysis by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region (4D Bubble Chart)
5.1.7. Analysis by Company / Organization Size, Region, Type of Metabolomics Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application (Grid Representation)
6. COMPANY COMPETITIVENESS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Benchmarking of Service Strength
6.3.2. Company Competitiveness Analysis: Benchmarking of Partnership activity
6.3.3. Company Competitiveness Analysis: Very Small Companies
6.3.4. Company Competitiveness Analysis: Small Companies
6.3.5. Company Competitiveness Analysis: Mid-Sized Companies
6.3.6. Company Competitiveness Analysis: Large and Very Large Companies
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. biocrates life sciences
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Creative Proteomics
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. DNA Xperts
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. Eremid Research Services
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. Human Metabolome Technologies (HMT)
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Metabo Profile
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Metabolon
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.9. MS-Omics
7.9.1. Company Overview
7.9.2. Recent Developments and Future Outlook
7.10. Novelgene Technologies
7.10.1. Company Overview
7.10.2. Recent Developments and Future Outlook
7.11. Synbio Technologies
7.11.1. Company Overview
7.11.2. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Metabolomics Service Providers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1. Analysis by Year and Type of Partnership
8.3.2.2. Analysis by Type of Partnership and Company Size
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Metabolomics Service(s) Offered
8.3.5. Analysis by Type of Metabolome Profiling Technique Used
8.3.6. Analysis by Area of Application
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1. Local and International Deals
8.3.8.2. Intercontinental and Intracontinental Deals
8.3.8.3. Analysis by Location of Headquarters of Partner
8.3.8.4. Analysis by Type of Partnership and Location of Headquarters of Partner
9. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEED IN METABOLOMICS
9.1. Chapter Overview
9.2. Unmet Need in Metabolomics
9.3. Sensitivity and Selectivity: Key Tools and Technologies
9.3.1. Key Assumptions and Methodology
9.3.2. Dynamic Nuclear Polarization (DNP)
9.3.3. Technology B
9.3.4. Technology C
9.3.5. Results and Discussion
9.4. Data Processing: Key Tools and Technologies
9.4.1. Key Assumptions and Methodology
9.4.2. Artificial Intelligence
9.4.3. Technology E
9.4.4. Technology F
9.4.5. Technology I
9.4.6. Technology J
9.4.7. Technology K
9.4.8. Quantum Computing
9.4.9. Trends in Research Activity
9.4.10. Extent of Innovation versus Associated Risks
9.4.11. Results and Discussion
9.4.12. Results and Discussion
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Metabolomics Services Market, 2022-2035
10.4. Metabolomics Services Market: Analysis by Area of Application, 2022 and 2035
10.4.1. Metabolomics Services Market for Biomarker Discovery, 2022- 2035
10.4.2. Metabolomics Services Market for Personalized Medicine, 2022-2035
10.4.3. Metabolomics Services Market for Drug Discovery, 2022-2035
10.4.4. Metabolomics Services Market for Disease Diagnostics, 2022- 2035
10.4.5. Metabolomics Services Market for Toxicological Testing, 2022-2035
10.5. Metabolomics Services Market: Analysis by Type of Metabolomics Service Offered, 2022 and 2035
10.5.1. Metabolomics Services Market for Targeted Metabolomics, 2022-2035
10.5.2. Metabolomics Services Market for Untargeted Metabolomics, 2022-2035
10.6. Metabolomics Services Market: Analysis by Type of Metabolome Profiling Technique Used, 2022 and 2035
10.6.1. Metabolomics Services Market for LC-MS Technique, 2022-2035
10.6.2. Metabolomics Services Market for GC-MS Technique, 2022-2035
10.6.3. Metabolomics Services Market for NMR Technique, 2022-2035
10.7. Metabolomics Services Market: Analysis by Type of End User, 2022 and 2035
10.7.1. Metabolomics Services Market for Academic / Research Institutes, 2022-2035
10.7.2. Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035
10.7.3. Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035
10.8. Metabolomics Services Market: Analysis by Key Geographical Regions, 2022 and 2035
10.8.1. Metabolomics Services Market in North America, 2022-2035
10.8.2. Metabolomics Services Market in Europe, 2022-2035
10.8.3. Metabolomics Services Market in Asia, 2022-2035
10.8.4. Metabolomics Services Market in Latin America, 2022-2035
10.8.5. Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035
10.8.6. Metabolomics Services Market in Rest of the World, 2022-2035
10.9. Concluding Remarks
11. CONCLUSION
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. BASF Metabolome Solutions
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Head of Metabolome Data Science
12.3. biocrates life sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Indian Partner (Eroth Technologies)
12.4. European Molecular Biology Laboratory (EMBL)
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Scientific Officer
12.5. MS-Omics
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Chief Executive Officer
12.6. Phylogene
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Chairman and Chief Executive Officer
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape (I/II)
Figure 2.2 Executive Summary: Overall Market Landscape (II/II)
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Metabolomics Process
Figure 3.2 Applications of Metabolomics
Figure 3.3 Challenges Related to Metabolomics
Figure 4.1 Metabolomics Service Providers: Distribution by Type of Service Provider
Figure 4.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Figure 4.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.5 Metabolomics Service Providers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 4.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Figure 4.10 Metabolomics Service Providers (Industry Players): Distribution by Type of Separation Technique
Figure 4.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Figure 4.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Figure 4.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 4.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Figure 4.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Figure 4.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Figure 4.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Figure 4.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Separation Technique Used
Figure 4.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Figure 4.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Figure 5.1 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Figure 5.2 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Figure 5.3 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Figure 5.4 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Figure 5.5 Key Insights: Distribution by Area of Application and Company / Organization Size
Figure 5.6 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Figure 5.7 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Figure 5.8 Key Insights: Distribution by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region
Figure 5.9 Key Insights: Distribution by Company / Organization Size, Region, Type of Metabolomic Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application
Figure 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Figure 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large and Very Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Distribution by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Type of Metabolomic Service(s) Offered
Figure 8.9 Partnerships and Collaborations: Distribution by Area of Application
Figure 8.10 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Figure 8.11 Most Active Players: Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Local and International Agreements
Figure 8.13 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.1 Value Creation Framework: Likely Sensitivity Enhancement by Implementation of Key Tools and Technologies
Figure 9.2 Value Creation Framework: Trends in Research Activity related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.3 Value Creation Framework: Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.4 Value Creation Framework: Extent of Innovation versus Associated Risk Matrix
Figure 9.5 Value Creation Framework: Comparison of Key Tools / Technologies
Figure 10.1 Global Metabolomics Services Market, 2022-2035 (USD Million)
Figure 10.2 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Figure 10.3 Metabolomics Services Market for Biomarker Discovery, 2022-2035 (USD Million)
Figure 10.4 Metabolomics Services Market for Personalized Medicine, 2022-2035 (USD Million)
Figure 10.5 Metabolomics Services Market for Disease Diagnostics, 2022-2035 (USD Million)
Figure 10.6 Metabolomics Services Market for Drug Discovery, 2022-2035 (USD Million)
Figure 10.7 Metabolomics Services Market for Toxicological Testing, 2022-2035 (USD Million)
Figure 10.8 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered 2022 and 2035
Figure 10.9 Metabolomics Services Market for Targeted Metabolomics, 2022-2035 (USD Million)
Figure 10.10 Metabolomics Services Market for Untargeted Metabolomics, 2022-2035 (USD Million)
Figure 10.11 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Figure 10.12 Metabolomics Services Market for LC-MS Technique, 2022-2035 (USD Million)
Figure 10.13 Metabolomics Services Market for GC-MS Technique, 2022-2035 (USD Million)
Figure 10.14 Metabolomics Services Market for NMR Technique, 2022-2035 (USD Million)
Figure 10.15 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Figure 10.16 Metabolomics Services Market for Academic / Research Institutes, 2022-2035 (USD Million)
Figure 10.17 Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035 (USD Million)
Figure 10.18 Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035 (USD Million)
Figure 10.19 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Figure 10.20 Metabolomics Services Market in North America, 2022-2035 (USD Million)
Figure 10.21 Metabolomics Services Market in Europe, 2022-2035 (USD Million)
Figure 10.22 Metabolomics Services Market in Asia, 2022-2035 (USD Million)
Figure 10.23 Metabolomics Services Market in Latin America, 2022-2035 (USD Million)
Figure 10.24 Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
Figure 10.25 Metabolomics Services Market in Rest of the World, 2022-2035 (USD Million)
Figure 10.26 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)
Figure 11.1 Concluding Remarks: Current Market Landscape
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Market Forecast (I/II)
Figure 11.4 Concluding Remarks: Market Forecast (II/II)
Table 3.1 Comparison between Mass Spectrometry and Nuclear Magnetic Resonance
Table 4.1 Metabolomics Service Providers: List of Players
Table 4.2 Metabolomics Service Providers: List of Industry Players
Table 4.3 Metabolomics Service Providers (Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.4 Metabolomics Service Providers (Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.5 Metabolomics Service Providers (Industry Players): Information on Type of Additional Service(s) Offered
Table 4.6 Metabolomics Service Providers (Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.7 Metabolomics Service Providers (Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.8 Metabolomics Service Providers (Industry Players): Information on Type of Biological Sample Analyzed
Table 4.9 Metabolomics Service Providers (Industry Players): Information on Source of Biological Sample
Table 4.10 Metabolomics Service Providers (Industry Players): Information on Area of Application
Table 4.11 Metabolomics Service Providers: List of Non-Industry Players
Table 4.12 Metabolomics Service Providers (Non-Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.13 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.14 Metabolomics Service Providers (Non-Industry Players): Information on Type of Additional Service(s) Offered
Table 4.15 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.16 Metabolomics Service Providers (Non-Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.17 Metabolomics Service Providers (Non-Industry Players): Information on Type of Biological Sample Analyzed
Table 4.18 Metabolomics Service Providers (Non-Industry Players): Information on Source of Biological Sample
Table 4.19 Metabolomics Service Providers (Non-Industry Players): Information on Area of Application
Table 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 6.3 Company Competitiveness Analysis: List of Very Small Players
Table 6.4 Company Competitiveness Analysis: List of Small Players
Table 6.5 Company Competitiveness Analysis: List of Mid-sized Players
Table 6.6 Company Competitiveness Analysis: List of Large and Very Large Players
Table 7.1 Metabolomics Service Providers: List of Companies Profiled
Table 7.2 biocrates life sciences: Company Overview
Table 7.3 biocrates life sciences: Recent Developments and Future Outlook
Table 7.4 Creative Proteomics: Company Overview
Table 7.5 DNA Xperts: Company Overview
Table 7.6 Eremid Research Services: Company Overview
Table 7.7 Eremid Research Services: Recent Developments and Future Outlook
Table 7.8 Human Metabolome Technologies (HMT): Company Overview
Table 7.9 Human Metabolome Technologies (HMT): Recent Developments and Future Outlook
Table 7.10 Metabo Profile: Company Overview
Table 7.11 Metabo Profile: Recent Developments and Future Outlook
Table 7.12 Metabolon: Company Overview
Table 7.13 Metabolon: Recent Developments and Future Outlook
Table 7.14 MS-Omics: Company Overview
Table 7.15 MS-Omics: Recent Developments and Future Outlook
Table 7.16 Novelgene Technologies: Company Overview
Table 7.17 Synbio Technologies: Company Overview
Table 7.18 Synbio Technologies: Recent Developments and Future Outlook
Table 8.1 Metabolomics Services: List of Collaborations, 2015-2021
Table 8.2 Metabolomics Services: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise)
Table 8.3 Metabolomics Services: Partnerships and Collaborations, Information on Metabolomics Service(s) Offered and Area of Application
Table 12.1 BASF Metabolome Solutions: Company Snapshot
Table 12.2 European Molecular Biology Laboratory (EMBL): Company Snapshot
Table 12.3 Phylogene: Company Snapshot
Table 13.1 Metabolomic Service Providers: Distribution by Type of Service Provider
Table 13.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Table 13.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Table 13.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Table 13.5 Metabolomics Service Providers (Industry Players): Distribution by Company
Table 13.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomic Service(s) Offered
Table 13.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Table 13.10 Metabolomics Service Providers (Industry Players): Distribution by Type Separation Technique Used
Table 13.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Table 13.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Table 13.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 13.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Table 13.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Table 13.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Table 13.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Metabolomics Service(s) Offered
Table 13.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Additional Service(s) Offered
Table 13.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Table 13.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Table 13.28 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Table 13.29 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Table 13.30 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Table 13.31 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Table 13.32 Key Insights: Distribution by Area of Application and Company / Organization Size
Table 13.33 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Table 13.34 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Table 13.35 Company Competitiveness Analysis: Benchmarking of Services Strength
Table 13.36 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 13.37 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Table 13.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.39 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.40 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.42 Partnerships and Collaborations: Distribution by Type of Metabolomics Service(s) Offered
Table 13.43 Partnerships and Collaborations: Distribution by Type of Metabolome Profiling Technique Used
Table 13.44 Partnerships and Collaborations: Distribution by Area of Application
Table 13.45 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Table 13.46 Most Active Players: Distribution by Number of Partnerships
Table 13.47 Partnerships and Collaborations: Local and International Agreements
Table 13.48 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 13.49 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner (Country-wise)
Table 13.50 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 13.51 Value Creation Framework: Distribution by Relative Sensitivity and Key Tools and Technologies
Table 13.52 Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Table 13.53 Value Creation Framework: Extent of Innovation versus Associated Risk Analysis
Table 13.54 Value Creation Framework: Implementation of Key Tools / Technologies
Table 13.55 Metabolomics Services Market, 2022-2035 (USD Million)
Table 13.56 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Table 13.57 Metabolomics Services Market for Biomarker Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.58 Metabolomics Services Market for Personalized Medicine, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.59 Metabolomics Services Market for Disease Diagnostics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.60 Metabolomics Services Market for Drug Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.61 Metabolomics Services Market for Toxicological Testing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.62 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered, 2022 and 2035
Table 13.63 Metabolomics Services Market for Targeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.64 Metabolomics Services Market for Untargeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.65 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Table 13.66 Metabolomics Services Market for LC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.67 Metabolomics Services Market for GC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.68 Metabolomics Services Market for NMR Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.69 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Table 13.70 Metabolomics Services Market for Academic / Research Institutes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.71 Metabolomics Services Market for Pharma / Biotech Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.72 Metabolomics Services Market for Contract Research Organizations (CROs), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.73 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Table 13.74 Metabolomics Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.75 Metabolomics Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.76 Metabolomics Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.77 Metabolomics Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.78 Metabolomics Services Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.79 Metabolomics Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.80 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)
Please reach out to our team for the details.